Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?

Overview

Journal Transl Oncol

Specialty Oncology

Date 2014 Nov 13

PMID 25389454

Citations 14

Authors

Leticia Mayor-Lopez

Elena Tristante

Mar Carballo-Santana

Estefania Carrasco-Garcia

Silvina Grasso

Pilar Garcia-Morales

Miguel Saceda

Juan Lujan

Jose Garcia-Solano

Fernando Carballo

Carlos de Torre

Isabel Martinez-Lacaci

Affiliations

Soon will be listed here.

Abstract

Nad(p)h: quinone oxidoreductase 1 (NQO1) enzyme and activity. However, colorectal LoVo cells still responded to both drugs in spite of having undetectable levels and activity of NQO1. Pharmacological and biologic inhibition of NQO1 did not confer resistance to 17-AAG in sensitive cell lines. Therefore, even though 17-AAG sensitivity is related to NQO1 protein levels and enzymatic activity, the absence of NQO1 does not necessarily convey resistance to 17-AAG in these cellular models. Moreover, NVP-AUY922 does not require NQO1 for its action and is a more potent inhibitor than 17-AAG in these cells. More importantly, we show in this report that NVP-AUY922 potentiates the inhibitory effects of chemotherapeutic agents, such as gemcitabine or oxaliplatin, and other drugs that are currently being evaluated in clinical trials as antitumor agents.

Citing Articles

Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells.

Ebrahimpour M, Mohammadian M, Pourheydar B, Moradi Z, Behrouzkia Z J Lasers Med Sci. 2022; 13:e9.

PMID: 35996484 PMC: 9392888. DOI: 10.34172/jlms.2022.09.

Effects of Heat Shock Protein 90 Inhibition In the Lungs.

Uddin M, Kubra K, Sonju J, Akhter M, Seetharama J, Barabutis N Med Drug Discov. 2020; 6.

PMID: 32728665 PMC: 7390472. DOI: 10.1016/j.medidd.2020.100046.

The HSP90 Inhibitor, AUY-922, Ameliorates the Development of Nitrogen Mustard-Induced Pulmonary Fibrosis and Lung Dysfunction in Mice.

Solopov P, Colunga Biancatelli R, Marinova M, Dimitropoulou C, Catravas J Int J Mol Sci. 2020; 21(13).

PMID: 32635192 PMC: 7369861. DOI: 10.3390/ijms21134740.

Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line.

Mohammadian M, Feizollahzadeh S, Mahmoudi R, Toofani Milani A, Rezapour-Firouzi S, Karimi Douna B Asian Pac J Cancer Prev. 2020; 21(6):1773-1778.

PMID: 32592377 PMC: 7568890. DOI: 10.31557/APJCP.2020.21.6.1773.

HSP90 inhibitor 17AAG attenuates sevoflurane-induced neurotoxicity in rats and human neuroglioma cells via induction of HSP70.

Liu M, Li M, Zhou Y, Zhou Q, Jiang Y J Transl Med. 2020; 18(1):166.

PMID: 32293462 PMC: 7158111. DOI: 10.1186/s12967-020-02332-w.

References

Jhaveri K, Taldone T, Modi S, Chiosis G . Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2011; 1823(3):742-55. PMC: 3288123. DOI: 10.1016/j.bbamcr.2011.10.008. View

Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2000; 103(2):211-25. DOI: 10.1016/s0092-8674(00)00114-8. View

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley J . Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 2006; 5(11):2676-84. DOI: 10.1158/1535-7163.MCT-06-0166. View

Sessa C, Shapiro G, Bhalla K, Britten C, Jacks K, Mita M . First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013; 19(13):3671-80. DOI: 10.1158/1078-0432.CCR-12-3404. View

Eccles S, Massey A, Raynaud F, Sharp S, Box G, Valenti M . NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008; 68(8):2850-60. DOI: 10.1158/0008-5472.CAN-07-5256. View

Gottesman M . Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53:615-27. DOI: 10.1146/annurev.med.53.082901.103929. View

Riese 2nd D, Stern D . Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998; 20(1):41-8. DOI: 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V. View

Jhaveri K, Ochiana S, Dunphy M, Gerecitano J, Corben A, Peter R . Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs. 2014; 23(5):611-28. PMC: 4161020. DOI: 10.1517/13543784.2014.902442. View

Ballestrero A, Garuti A, Cirmena G, Rocco I, Palermo C, Nencioni A . Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets. 2012; 12(4):316-28. DOI: 10.2174/156800912800190956. View

10.

Neckers L . Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002; 8(4 Suppl):S55-61. DOI: 10.1016/s1471-4914(02)02316-x. View

11.

Ambudkar S, Dey S, Hrycyna C, Ramachandra M, Pastan I, Gottesman M . Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999; 39:361-98. DOI: 10.1146/annurev.pharmtox.39.1.361. View

12.

Schulte T, Blagosklonny M, Ingui C, Neckers L . Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem. 1995; 270(41):24585-8. DOI: 10.1074/jbc.270.41.24585. View

13.

Porter J, Fritz C, Depew K . Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol. 2010; 14(3):412-20. DOI: 10.1016/j.cbpa.2010.03.019. View

14.

Hong D, Banerji U, Tavana B, George G, Aaron J, Kurzrock R . Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2012; 39(4):375-87. DOI: 10.1016/j.ctrv.2012.10.001. View

15.

Blagosklonny M, Toretsky J, Neckers L . Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 1995; 11(5):933-9. View

16.

Siegel D, Shieh B, Yan C, Kepa J, Ross D . Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J Pharmacol Exp Ther. 2010; 336(3):874-80. PMC: 3061536. DOI: 10.1124/jpet.110.176438. View

17.

Yamaki H, Ariga H . Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group. J Antibiot (Tokyo). 1989; 42(4):604-10. DOI: 10.7164/antibiotics.42.604. View

18.

Gaspar N, Sharp S, Pacey S, Jones C, Walton M, Vassal G . Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 2009; 69(5):1966-75. PMC: 2652695. DOI: 10.1158/0008-5472.CAN-08-3131. View

19.

Uehara Y, Hori M, Takeuchi T, Umezawa H . Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol. 1986; 6(6):2198-206. PMC: 367760. DOI: 10.1128/mcb.6.6.2198-2206.1986. View

20.

Simard E, Ward E, Siegel R, Jemal A . Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62(2):118-28. DOI: 10.3322/caac.20141. View